Asare O, Shim L, Lee C, Delgado J, Quailes N, Zavala K
Cell Death Discov. 2025; 11(1):80.
PMID: 40021617
PMC: 11871011.
DOI: 10.1038/s41420-025-02353-8.
Pan W, Tsokos M, Li W, Tsokos G
Immunometabolism (Cobham). 2025; 7(1):e00056.
PMID: 39944077
PMC: 11812671.
DOI: 10.1097/IN9.0000000000000056.
Liu Y, Li S, Robertson R, Granet J, Aubry I, Filippelli R
Life Sci Alliance. 2024; 8(1).
PMID: 39477543
PMC: 11527974.
DOI: 10.26508/lsa.202402831.
Chatterjee P, Canale V, King S, Shawki A, Lei H, Haddad M
medRxiv. 2024; .
PMID: 39399045
PMC: 11469354.
DOI: 10.1101/2024.09.26.24314341.
Chatterjee P, Spalinger M, Acevedo C, Gries C, Manz S, Canale V
bioRxiv. 2024; .
PMID: 39386684
PMC: 11463449.
DOI: 10.1101/2024.09.24.614848.
Protein tyrosine phosphatase non-receptor type 2 (PTPN2) gene polymorphisms (rs2542151, rs7234029) in Egyptian Behçet's disease patients: a preliminary report.
Attia D, Alkaffas M, Eissa M, Rashed L, Khattab R, Elzanaty R
Clin Rheumatol. 2024; 43(11):3439-3448.
PMID: 39320556
PMC: 11489223.
DOI: 10.1007/s10067-024-07128-7.
3-Benzylaminomethyl Lithocholic Acid Derivatives Exhibited Potent and Selective Uncompetitive Inhibitory Activity Against Protein Tyrosine Phosphatase 1B (PTP1B).
Mendoza-Jasso M, Perez-Villanueva J, Alvarado-Rodriguez J, Gonzalez-Andrade M, Cortes-Benitez F
ACS Omega. 2024; 9(30):33224-33238.
PMID: 39100322
PMC: 11292843.
DOI: 10.1021/acsomega.4c04948.
Haploinsufficiency in PTPN2 leads to early-onset systemic autoimmunity from Evans syndrome to lupus.
Jeanpierre M, Cognard J, Tusseau M, Riller Q, Bui L, Berthelet J
J Exp Med. 2024; 221(9.
PMID: 39028869
PMC: 11259789.
DOI: 10.1084/jem.20232337.
Protein Tyrosine Phosphatase 1B (PTP1B): A Comprehensive Review of Its Role in Pathogenesis of Human Diseases.
Kolodziej-Sobczak D, Sobczak L, Laczkowski K
Int J Mol Sci. 2024; 25(13).
PMID: 39000142
PMC: 11241624.
DOI: 10.3390/ijms25137033.
Anti-Obesity Therapeutic Targets Studied In Silico and In Vivo: A Systematic Review.
de Medeiros W, Gomes A, Aguiar A, de Queiroz J, Bezerra I, da Silva-Maia J
Int J Mol Sci. 2024; 25(9).
PMID: 38731918
PMC: 11083175.
DOI: 10.3390/ijms25094699.
Immunotherapeutic implications of negative regulation by protein tyrosine phosphatases in T cells: the emerging cases of PTP1B and TCPTP.
Perez-Quintero L, Abidin B, Tremblay M
Front Med (Lausanne). 2024; 11:1364778.
PMID: 38707187
PMC: 11066278.
DOI: 10.3389/fmed.2024.1364778.
Targeting Protein Tyrosine Phosphatases to Improve Cancer Immunotherapies.
Salmond R
Cells. 2024; 13(3.
PMID: 38334623
PMC: 10854786.
DOI: 10.3390/cells13030231.
Protein tyrosine phosphatases as emerging targets for cancer immunotherapy.
Qu Z, Dong J, Zhang Z
Br J Pharmacol. 2023; .
PMID: 38116815
PMC: 11186978.
DOI: 10.1111/bph.16304.
PTPN2 Regulates Metabolic Flux to Affect β-Cell Susceptibility to Inflammatory Stress.
Kim Y, Kim Y, Wells K, Sarbaugh D, Guney M, Tsai C
Diabetes. 2023; 73(3):434-447.
PMID: 38015772
PMC: 10882156.
DOI: 10.2337/db23-0355.
X-CHIME enables combinatorial, inducible, lineage-specific and sequential knockout of genes in the immune system.
LaFleur M, Lemmen A, Streeter I, Nguyen T, Milling L, Derosia N
Nat Immunol. 2023; 25(1):178-188.
PMID: 38012416
PMC: 10881062.
DOI: 10.1038/s41590-023-01689-6.
The PTPN2/PTPN1 inhibitor ABBV-CLS-484 unleashes potent anti-tumour immunity.
Baumgartner C, Ebrahimi-Nik H, Iracheta-Vellve A, Hamel K, Olander K, Davis T
Nature. 2023; 622(7984):850-862.
PMID: 37794185
PMC: 10599993.
DOI: 10.1038/s41586-023-06575-7.
Targeting protein phosphatases in cancer immunotherapy and autoimmune disorders.
Stanford S, Bottini N
Nat Rev Drug Discov. 2023; 22(4):273-294.
PMID: 36693907
PMC: 9872771.
DOI: 10.1038/s41573-022-00618-w.
Immune checkpoint PTPN2 predicts prognosis and immunotherapy response in human cancers.
Tang X, Sui X, Liu Y
Heliyon. 2023; 9(1):e12873.
PMID: 36685446
PMC: 9852697.
DOI: 10.1016/j.heliyon.2023.e12873.
Combination Approaches to Target PD-1 Signaling in Cancer.
Moore E, Strazza M, Mor A
Front Immunol. 2022; 13:927265.
PMID: 35911672
PMC: 9330480.
DOI: 10.3389/fimmu.2022.927265.
Computational Methods in Cooperation with Experimental Approaches to Design Protein Tyrosine Phosphatase 1B Inhibitors in Type 2 Diabetes Drug Design: A Review of the Achievements of This Century.
Campos-Almazan M, Hernandez-Campos A, Castillo R, Sierra-Campos E, Valdez-Solana M, Avitia-Dominguez C
Pharmaceuticals (Basel). 2022; 15(7).
PMID: 35890163
PMC: 9322956.
DOI: 10.3390/ph15070866.